March 18, 2026
1 min read

Sandoz expands biosim collab with Samsung Bioepis, sets sights on Takeda’s Entyvio

Sandoz has struck a deal with Samsung Bioepis to commercialize up to five biosimilars, with the first being SB36, a copycat of Takeda’s Entyvio, which is being developed by the South Korea-based biosimilars specialist.

Leave a Reply

Your email address will not be published.

Previous Story

Ultra-Processed Foods Linked To Heart Attack, Stroke, Cardiac Arrest MedNews

Next Story

Women More Likely To Survive Cancer Than Men — At A Cost MedNews

Previous Story

Ultra-Processed Foods Linked To Heart Attack, Stroke, Cardiac Arrest MedNews

Next Story

Women More Likely To Survive Cancer Than Men — At A Cost MedNews

Latest from Blog

Go toTop